Clinical Trial Update: Rifampicin at High Dose for Difficult-to-Treat Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining high-dose rifampicin for difficult-to-treat tuberculosis is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Rifampicin

Snippet

Sponsor: Hospital Universitari Vall d'Hebron Research Institute | Conditions: Tuberculosis | Phase 2 | Status: UNKNOWN